Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells

Breast Cancer Research and Treatment

Volumn 56, Issue 2, 1999, Pages 187-196

  Hansen, Rhonda K ^a   Parra, Irma ^a   Lemieux, Pierre ^b   Oesterreicht, Steffi ^a   Hilsenbeck, Susan G ^a   Fuqua, Suzanne A W ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b Angiotech Pharmaceuticals Inc   (Canada)

Author keywords

Apoptosis; Breast cancer; Doxorubicin; Hsp27; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; HEAT SHOCK PROTEIN 27;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL PROTECTION; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032747966     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1006207009260     Document Type: Article

References (29)

1. Hannun YA: Apopotosis and the dilemma of cancer chemotherapy. Blood 89: 1845-1853, 1997
2. Harris, AL, Hockhauscr D: Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 31: 205-213, 1992
3. Robert J, Larsen AK: Drug resistance to topoisomerase II inhibitors. Biochemie 80: 247-254, 1998
4. Lowe SW, Ruley HE, Jacks, T, Housman DF: p53-dependent apopotosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967, 1993
5. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y, Cossman J: Bcl-2 protein inhibits etoposide-induced apopotosis through its effects on events subsequent to isomerase II-induced strand breaks and their repair. Cancer Res 53: 4251-4256, 1993
6. Ciocca RD, Fuqua SAW, Lock-Lim S, Toft DO, Welch WJ, McGuire WL: Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res 52: 2648-3654, 1992
7. Oesterreich S, Weng C-N, Qiu M, Hilsenbeck SG, Osborne CK, Fuqua SAW: The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Res 53: 4443-4448, 1993
8. Huot J, Roy G, Lambert H, Chretien P, Landry J: Increased survival after treatments with anticancer agents of Chinese hamster cells expressing the human Mr 27 000 heat shock protein. Cancer Res 51: 5245-5252, 1991
9. Walker PR, Smirch C, Youdale T, Leblanc J, Whitfield JF, Sikorska M: Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res 51: 1078-1985, 1991
10. Lemieux P, Oesterreich S, Lawrence JA, Steeg PS, Hilsenbeck SG, Harvey JM, Fuqua SAW: The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. Invasion Metastasis 17: 113-123, 1998
11. Hilsenbeck SG, Friedrichs WG, Schiff R, O'Connell P, Hansen RK, Osborne CK, Fuqua SAW: Statistical analysis of microarray expression data as applied to the problem of tamoxifen resistance. J CNatl Cancer Inst 91: 1998
12. Krishan A: Rapid DNA content analysis by the propidium iodide-hypotonic citrate method. Meth Cell Biol 33: 121-125, 1990
13. Strasser A, Huang DC, Vaux DL: The role of the bcl-2/ced-9 gene fianily in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochim Biophys Acta 1333: F151-F178, 1997
14. Mehlen P, Schulze-Osthoff K, Arrigo AP: Small stress proteins as novel regulators of apoptosis. J Biol Cheme 271: 16510-16514, 1996
15. Mehlen P, Mehlen A, Godet J, Arrigo AP: Hsp27 as a switch between differentiation and apoptosis in murine embryonic stem cells. J Biol Chem 272: 31657-31665, 1997
16. Oesterreich S, Hilsenbeck S, Ciocca DR, Allred CD, Clark GC, Chamness GC, Osborne CK, Fuqua SAW: The small heat shock protein hsp27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res 2: 1199-1206, 1996
17. Wang H, Jiang Z, Wong YW, Dalton WS, Futscher BW, Chan VTW: Decreased CP-I (NF-Y) activity results in transcriptional down-regulation of topoisomerase IIα in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226. Biochem Biophys Res Commun 231: 217-224, 1997
18. McPherson JP, Deffie AM, Jones NR, Brown GA, Deuchars KL, Goldenberg GJ: Selective sensitization of adriamycin-resistant P388 murine leukemia calls to antineoplastic agents following transfection with human DNA topoisomerase IIα. Anticancer Res 17: 4243-4252, 1997
19. Smith K, Houlbrook S, Greenall M, Carmichael J, Harris AL: Topoisomemse IIα co-amplification with erbB-2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitozantrone sensitivity. Oncogene 8: 933-938, 1993
20. Kim R, Hirabayashi N, Nishiyama M, Sacki S, Toge T, Okada K: Expression of MDRI, GSTπ and topoisomerase II as an indicator of clinical response to adriamycin. Anticancer Res 11: 429-432, 1991
21. Sandri MI, Hockhauser D, Ayton P, Camplejohn RC, Whitehuuse R, Turley H, Gatter K, Hickson ID, Harris AL: Differential expression of the topoisomerase IIα and β genes in human breast cancers. Br J Cancer 73: 1518-1524, 1996
22. Garrido C, Mehlen P, Fromentin A, Hammann A, Assem M, Arrigo AP, Chauffert B: Inconstant association between 27-kDa heat-shock protein (Hsp27) content and doxorubicin resistance in human colon cancer cells. Eur J Biochem 237: 653-659, 1996
23. Hashimoto S, Jing Y, Kawazoc N, Masuda Y, Nakajo S, Yoshida T, Kuroiwa Y, Nakaya K: Bufalin reduces thc level of topoisomerase II in human leukemia cells and affects the cytotoxicity of anticancer drugs. Leuk Res 21: 875-883, 1997
24. Bartek J, Iggo R, Gannon J, Lane DP: Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5: 893-899, 1990
25. , Guenal I, Fraisse CS, Gaumer S, Mignotte B: Bcl-2 and hsp27 act at different levels to suppress programmed cell death. Oncogene 15: 347-360, 1997
26. Mehlen P, Preville X, Charcyron P, Briolay J, Klemenz R, Arrigo AP: Constitutive expression of human hsp27, Drosophila hsp27, or human αβ-crystallin confers resistance to TNF-and oxidative stress-induced cytotoxicity in stably transfected murine L929 fibroblasts. J Immunol 154: 363-374, 1995
27. Mueller H, Flury N, Liu R, Scheidegger S, Eppenberger U: Tumour necrosis factor and interferon are selectively cytoslatic in vitro for hormone-dependent and hormone-independent human breast cancer cells. Eur J Cancer 23A: 2312-2318. 1996
28. Keane MM, Ettenberg SA, Lowrey GA, Russell EK. Lipkowitz S: Fas expression and function in normal and malignant breast cell lines. Cancer Res 56, 4791-4798, 1996
29. Jacobson MD: Reactive oxygen species and programmed cell death. Trends Biochem Sci 21: 83-86, 1996